• Designing a development strategy for Phase 2 and beyond
• Strengthening the link between clinical progress and CMC readiness
• Leveraging partnerships and CDMOs for clinical-stage manufacturing
• Anticipating regulatory needs while remaining agile
• Building a scalable platform without overextending resources